Precigen, Inc.
A biopharmaceutical company in Germantown, Maryland, that develops precision medicines for cancer, autoimmune disorders, and infectious diseases. It grew out of Intrexon, a synthetic biology firm founded in 1998, and in 2020 the whole company rebranded as Precigen to focus entirely on human health. Its name blends "precision" and "genetics," and its UltraCAR-T platform can engineer a patient's own immune cells overnight at the hospital using a non-viral "Sleeping Beauty" gene-delivery system.
Item 4 of the Original Schedule 13D is hereby amended and supplemented as follows: The information set forth in Items 3 and 6 is incorporated herein by reference. The Selling Entities sold a total of 4,772,781 shares of Common Stock in open market transactions on March 30, 2026, for aggregate net proceeds of approximately $15,581,221.
Item 4 of the Original Schedule 13D is hereby amended and supplemented as follows: The information set forth in Items 3 and 6 is incorporated herein by reference. The Selling Entities sold a total of 4,772,781 shares of Common Stock in open market transactions on March 30, 2026, for aggregate net proceeds of approximately $15,581,221.
Item 4 of the Original Schedule 13D is hereby amended and supplemented as follows: The information set forth in Items 3 and 6 is incorporated herein by reference. The Selling Entities sold a total of 4,772,781 shares of Common Stock in open market transactions on March 30, 2026, for aggregate net proceeds of approximately $15,581,221.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| Ares Trading SA | 13G/APassive | 4.9% | 17.47M | Aug 7, 2026 |
| Merck Serono SA, Aubonne, Switzerland, an affiliate of Merck KGaA, Darmstadt | 13G/APassive | 4.9% | 17.47M | Aug 7, 2026 |
| Merck KGaA, Darmstadt, Germany | 13G/APassive | 4.9% | 17.47M | Aug 7, 2026 |
| E. Merck KG, Darmstadt Germany | 13G/APassive | 4.9% | 17.47M | Aug 7, 2026 |
| Point72 Asset Management, L.P. | 13G/APassive | 1.9% | 6.74M | May 15, 2026 |
| Point72 Capital Advisors, Inc. | 13G/APassive | 1.9% | 6.74M | May 15, 2026 |
| Steven A. Cohen | 13G/APassive | 1.9% | 6.74M | May 15, 2026 |
| RANDAL J. KIRK | 13D/AActivist | 35.9% | 133.96M | Mar 31, 2026 |
Item 4 of the Original Schedule 13D is hereby amended and supplemented as follows: The information set forth in Items 3 and 6 is incorporated herein by reference. The Selling Entities sold a total of 4,772,781 shares of Common Stock in open market transactions on March 30, 2026, for aggregate net proceeds of approximately $15,581,221. | ||||
| R.J. KIRK DECLARATION OF TRUST | 13D/AActivist | 26.1% | 97.34M | Mar 31, 2026 |
Item 4 of the Original Schedule 13D is hereby amended and supplemented as follows: The information set forth in Items 3 and 6 is incorporated herein by reference. The Selling Entities sold a total of 4,772,781 shares of Common Stock in open market transactions on March 30, 2026, for aggregate net proceeds of approximately $15,581,221. | ||||
| THIRD SECURITY, LLC | 13D/AActivist | 5.9% | 21.84M | Mar 31, 2026 |
Item 4 of the Original Schedule 13D is hereby amended and supplemented as follows: The information set forth in Items 3 and 6 is incorporated herein by reference. The Selling Entities sold a total of 4,772,781 shares of Common Stock in open market transactions on March 30, 2026, for aggregate net proceeds of approximately $15,581,221. | ||||